Ritin Mohindra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ritin Mohindra has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Deep Dutta
Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi, India
6 shared publications - Vikas Suri
Division of Clinical Infectious Diseases, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
5 shared publications - Ashish Bhalla
Division of Clinical Infectious Diseases, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
3 shared publications - Meha Sharma
Department of Rheumatology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India
3 shared publications - Rachna Rohilla
Affiliation Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Bathinda, Bathinda, Punjab, India
3 shared publications Roshan Mathew
Department of Emergency Medicine, All India Institute of Medical Sciences, New Delhi, India
3 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46446
Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis
Background: Semaglutide is not yet approved for type 1 diabetes (T1D), but increasing evidence indicates it could offer clinical benefits for T1D patients, particularly those with overweight or obesity. Currently, no systematic review or meta-analysis has assessed semaglutide’s effectiveness in adults with T1D with overweight or obesity; this systematic review and meta-analysis aims to fill that knowledge gap. Methods: Electronic databases were searched for articles on semaglutide use in adults with T1D with overweight or obesity. Co-primary outcomes were the percent changes in body weight and glycated hemoglobin from baseline; secondary outcomes were changes in total daily dose of insulin, glycemic variability, and adverse events. Statistical analysis was performed with RStudio software (Posit Software, PBC, Boston ), and results are presented as mean differences (MDs) along with 95% confidence intervals. Results: Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed. All studies had a low risk of bias. Semaglutide use was associated with reductions in body weight from baseline at 3 months (MD −3.27% [−6.07 to −0.47]), 6 months (MD −6.53% [−8.44 to −4.63]), and 12 months (MD −7.6% [−8.16 to −7.04]). There was also a reduction in glycated hemoglobin from baseline at 3 months (MD −0.54% [−0.62 to −0.46]), 6 months (MD −0.55% [−0.71 to −0.40]), and 12 months (MD −0.6% [−0.72 to −0.48]). Three months (MD −0.05 units/kg/d [−0.06 to −0.03]) and 6 months (MD −0.07 units/kg/d [−0.13 to −0.01]) but not 12 months (MD −0.00 units/kg/d [−0.06 to 0.05]) of semaglutide therapy were associated with a reduction in total daily dose of insulin. Time in range (MD 4.62% [0.85 to 8.39]) and time above range (MD −8.97% [−16.41 to −1.53]) improved after 3 months of semaglutide use. Adverse event data were scarce and mostly gastrointestinal. Conclusion: In adults with T1D having overweight or obesity, short-term semaglutide effectively promotes weight loss, improves glycemic control, and reduces insulin requirements. More long-term randomized controlled trials with a diverse group of participants are needed to incorporate semaglutide into the routine clinical management of these patients.
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46446
Open AccessImpact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis
Background: Semaglutide is not yet approved for type 1 diabetes (T1D), but increasing evidence indicates it could offer clinical benefits for T1D patients, particularly those with overweight or obesity. Currently, no systematic review or meta-analysis has assessed semaglutide’s effectiveness in adults with T1D with overweight or obesity; this systematic review and meta-analysis aims to fill that knowledge gap. Methods: Electronic databases were searched for articles on semaglutide use in adults with T1D with overweight or obesity. Co-primary outcomes were the percent changes in body weight and glycated hemoglobin from baseline; secondary outcomes were changes in total daily dose of insulin, glycemic variability, and adverse events. Statistical analysis was performed with RStudio software (Posit Software, PBC, Boston ), and results are presented as mean differences (MDs) along with 95% confidence intervals. Results: Data from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed. All studies had a low risk of bias. Semaglutide use was associated with reductions in body weight from baseline at 3 months (MD −3.27% [−6.07 to −0.47]), 6 months (MD −6.53% [−8.44 to −4.63]), and 12 months (MD −7.6% [−8.16 to −7.04]). There was also a reduction in glycated hemoglobin from baseline at 3 months (MD −0.54% [−0.62 to −0.46]), 6 months (MD −0.55% [−0.71 to −0.40]), and 12 months (MD −0.6% [−0.72 to −0.48]). Three months (MD −0.05 units/kg/d [−0.06 to −0.03]) and 6 months (MD −0.07 units/kg/d [−0.13 to −0.01]) but not 12 months (MD −0.00 units/kg/d [−0.06 to 0.05]) of semaglutide therapy were associated with a reduction in total daily dose of insulin. Time in range (MD 4.62% [0.85 to 8.39]) and time above range (MD −8.97% [−16.41 to −1.53]) improved after 3 months of semaglutide use. Adverse event data were scarce and mostly gastrointestinal. Conclusion: In adults with T1D having overweight or obesity, short-term semaglutide effectively promotes weight loss, improves glycemic control, and reduces insulin requirements. More long-term randomized controlled trials with a diverse group of participants are needed to incorporate semaglutide into the routine clinical management of these patients.
- 3 February 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (2) , e70106
Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
Aims: No meta‐analysis has holistically analyzed and summarized the efficacy and safety of tocilizumab in polymyalgia rheumatica (PMR). We undertook this meta‐analysis to address this knowledge‐gap.Methods: Electronic databases were searched for RCTs involving patients living with PMR receiving tocilizumab in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate percentage of patients able to achieve C‐reactive protein PMR assessment score (CRP‐PMR‐AS) < 10 or prednisolone dose < 5 mg/day or > 10 mg/dL decline in prednisolone from baseline. Secondary outcomes were to determine percentage of patients able to totally stop prednisolone and adverse‐events.Results: From initially screened 115 articles, data from 2 RCTs (136 patients) was analyzed. In addition, a descriptive analysis of 8 observational studies (356 patients) was also done. After 24‐weeks of clinical use, patients with PMR receiving tocilizumab had significantly higher chances of achieving composite primary end‐point defined as CRP‐PMR‐AS < 10 and either prednisone dosage < 5 mg/day or decrease in prednisolone dosage by > 10 mg/day compared to baseline [odds ratio (OR) 4.89 (95% CI: 2.34–10.23); p < 0.001; I2 = 0%], compared to placebo. Patients with PMR receiving tocilizumab also had significantly higher chances of being able to stop prednisolone compared to placebo [OR 4.45 (95% CI: 2.06–9.61); p < 0.001; I2 = 0%]. Occurrence of total adverse‐events [risk ratio (RR) 1.24 (95% CI: 0.50–3.12); p = 0.64; I2 = 0%], adverse‐events leading to treatment discontinuation [RR 0.45 (95% CI: 0.10–2.02); p = 0.29; I2 = 17%], and infections [RR 1.71 (95% CI: 0.83–3.52); p = 0.14; I2 = 6%] were comparable in patients receiving tocilizumab as compared to placebo. Observational studies have noted lung infections, neutropenia and increased cholesterol with tocilizumab use.Conclusion: Tocilizumab is well tolerated and is effective for managing PMR. Tocilizumab is an effective glucocorticoid sparing agent in PMR.
- 3 February 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (2) , e70106
Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
Aims: No meta‐analysis has holistically analyzed and summarized the efficacy and safety of tocilizumab in polymyalgia rheumatica (PMR). We undertook this meta‐analysis to address this knowledge‐gap.Methods: Electronic databases were searched for RCTs involving patients living with PMR receiving tocilizumab in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate percentage of patients able to achieve C‐reactive protein PMR assessment score (CRP‐PMR‐AS) < 10 or prednisolone dose < 5 mg/day or > 10 mg/dL decline in prednisolone from baseline. Secondary outcomes were to determine percentage of patients able to totally stop prednisolone and adverse‐events.Results: From initially screened 115 articles, data from 2 RCTs (136 patients) was analyzed. In addition, a descriptive analysis of 8 observational studies (356 patients) was also done. After 24‐weeks of clinical use, patients with PMR receiving tocilizumab had significantly higher chances of achieving composite primary end‐point defined as CRP‐PMR‐AS < 10 and either prednisone dosage < 5 mg/day or decrease in prednisolone dosage by > 10 mg/day compared to baseline [odds ratio (OR) 4.89 (95% CI: 2.34–10.23); p < 0.001; I2 = 0%], compared to placebo. Patients with PMR receiving tocilizumab also had significantly higher chances of being able to stop prednisolone compared to placebo [OR 4.45 (95% CI: 2.06–9.61); p < 0.001; I2 = 0%]. Occurrence of total adverse‐events [risk ratio (RR) 1.24 (95% CI: 0.50–3.12); p = 0.64; I2 = 0%], adverse‐events leading to treatment discontinuation [RR 0.45 (95% CI: 0.10–2.02); p = 0.29; I2 = 17%], and infections [RR 1.71 (95% CI: 0.83–3.52); p = 0.14; I2 = 6%] were comparable in patients receiving tocilizumab as compared to placebo. Observational studies have noted lung infections, neutropenia and increased cholesterol with tocilizumab use.Conclusion: Tocilizumab is well tolerated and is effective for managing PMR. Tocilizumab is an effective glucocorticoid sparing agent in PMR.
- Open Access
Building Neurovascular tissue from autologous blood for modeling brain activity
There are no faithful individualized stem cell-based bioengineered neuro-vascularized models that can recapitulate the physiological hemodynamic phenomenon of neuro-vascular coupling (NVC)-the principal behind BOLD (blood oxygen level-dependent) signal in functional neuroimaging, thereby dissuading the research in exploring the brain activity-based investigative studies in neurological/neurosensory diseases. This encouraged us to establish a preclinical optoacoustic (Hb/dHb hemoglobin/deoxyhemoglobin) imaging-competent in vitro neuro-vascularized model by employing a novel cellular reprograming PITTRep (Plasma Induced Transcriptomics/ epi-Transcriptomics Reprograming) approach. The current reprograming approach is based on coaxing autologous blood components to ecto-mesodermal lineage intermediates that can subsequently self-pattern into neurovascular tissue by harnessing the hemorheological properties of RBCs. The nature of blood flow is non-Newtonian and is a function of RBC concentration /haematocrit when they flow through the regions of low shear rates as seen in cerebral microcirculation. The current reprograming approach is a modification of our previous cellular reprograming approach that employed a Newtonian plasma fluid. The autologous blood-derived neurovascular tissue is free from exogenous genetic modification, external growth factors, and induced pluripotent stem cell (iPSC) derivation. This model uniquely integrates functional vasculature and neurogenesis. The current reprogramming approach resulted (in part) serendipitously while testing a potential (yet completely unexplored) hypothesis of haemodynamic reprograming by leveraging the fluid mechanic feature of blood erythrocytes as seen in thrombus formation during cerebral ischemic stroke, that is characterized by physiologically intriguing yet clinically meaningful neurological recovery (neuroplasticity) during an early time window. The current study attempted to induce “a post stroke-like model” of adult neurogenesis with functional synaptogenesis by instructing autologous blood components into thrombus formation through incorporation of erythrocytes in varying concentrations. We tried to instruct adult neurogenesis and neuroplasticity (a relatively non-resilient phenomenon under in vitro conditions) by co-induction of a neuro-vascular niche (NVN). These NVNs are marked by dendrites, synapses, astrogliosis, microglia activation, and growth factor signaling, thus phenocopying molecular and cellular aspects of post-stroke recovery window. The induction of neuro-vascularized niches and functional neuro-vascular coupling (NVC) was characterized by confocal microscopy, scanning electron microscopy, proteomic profiling, and Hb/dHb spectra based optoacoustic imaging. The blood thrombus formation was checked by rotational thromboelastometry (ROTEM), and switching of adult-to-embryonic hemoglobin was confirmed by routine hemoglobin typing. We also attempted to establish patient-specific neuro-vascularized niches from autologous blood of sensorineural hearing loss (SNHL) patients. The individualized neovascularised tissues are intended to be employed for investigating deregulated synaptic plasticity/ long term potentiation underlying poor auditory comprehension outcomes in school going kids suffering from SNHL that greatly compromises their academic performance and socio-behavioural-cognitive development. The attendant multiomics of patient-specific NVNs may have potential implications in developing stem-cell based therapies for neurosensory and cerebrovascular diseases.
Open AccessBuilding Neurovascular tissue from autologous blood for modeling brain activity
There are no faithful individualized stem cell-based bioengineered neuro-vascularized models that can recapitulate the physiological hemodynamic phenomenon of neuro-vascular coupling (NVC)-the principal behind BOLD (blood oxygen level-dependent) signal in functional neuroimaging, thereby dissuading the research in exploring the brain activity-based investigative studies in neurological/neurosensory diseases. This encouraged us to establish a preclinical optoacoustic (Hb/dHb hemoglobin/deoxyhemoglobin) imaging-competent in vitro neuro-vascularized model by employing a novel cellular reprograming PITTRep (Plasma Induced Transcriptomics/ epi-Transcriptomics Reprograming) approach. The current reprograming approach is based on coaxing autologous blood components to ecto-mesodermal lineage intermediates that can subsequently self-pattern into neurovascular tissue by harnessing the hemorheological properties of RBCs. The nature of blood flow is non-Newtonian and is a function of RBC concentration /haematocrit when they flow through the regions of low shear rates as seen in cerebral microcirculation. The current reprograming approach is a modification of our previous cellular reprograming approach that employed a Newtonian plasma fluid. The autologous blood-derived neurovascular tissue is free from exogenous genetic modification, external growth factors, and induced pluripotent stem cell (iPSC) derivation. This model uniquely integrates functional vasculature and neurogenesis. The current reprogramming approach resulted (in part) serendipitously while testing a potential (yet completely unexplored) hypothesis of haemodynamic reprograming by leveraging the fluid mechanic feature of blood erythrocytes as seen in thrombus formation during cerebral ischemic stroke, that is characterized by physiologically intriguing yet clinically meaningful neurological recovery (neuroplasticity) during an early time window. The current study attempted to induce “a post stroke-like model” of adult neurogenesis with functional synaptogenesis by instructing autologous blood components into thrombus formation through incorporation of erythrocytes in varying concentrations. We tried to instruct adult neurogenesis and neuroplasticity (a relatively non-resilient phenomenon under in vitro conditions) by co-induction of a neuro-vascular niche (NVN). These NVNs are marked by dendrites, synapses, astrogliosis, microglia activation, and growth factor signaling, thus phenocopying molecular and cellular aspects of post-stroke recovery window. The induction of neuro-vascularized niches and functional neuro-vascular coupling (NVC) was characterized by confocal microscopy, scanning electron microscopy, proteomic profiling, and Hb/dHb spectra based optoacoustic imaging. The blood thrombus formation was checked by rotational thromboelastometry (ROTEM), and switching of adult-to-embryonic hemoglobin was confirmed by routine hemoglobin typing. We also attempted to establish patient-specific neuro-vascularized niches from autologous blood of sensorineural hearing loss (SNHL) patients. The individualized neovascularised tissues are intended to be employed for investigating deregulated synaptic plasticity/ long term potentiation underlying poor auditory comprehension outcomes in school going kids suffering from SNHL that greatly compromises their academic performance and socio-behavioural-cognitive development. The attendant multiomics of patient-specific NVNs may have potential implications in developing stem-cell based therapies for neurosensory and cerebrovascular diseases.
- Open Access
- 31 July 2024
- Published by Bangladesh Academy of Sciences in Bangladesh Medical Journal
- Vol. 52 (2) , 15-19
Clinical, Microbiological Profile and Antibiotics Use in Admitted Patients of Urinary Tract Infection
Urinary tract infections (UTI) can vary from simple cystitis to pyelonephritis with severe sepsis. The objective of this study is to provide information about the clinical and microbiological profile of admitted patients of urinary tract infection, patterns of organisms isolated, antibiotic sensitivity pattern and antibiotics use. It was a prospective observational study conducted on 40 patients age >14 years admitted with diagnosis of UTI based on clinical and microbiological criteria over 8 months at a tertiary care hospital in North India. Data was collected for the clinical, microbiological profile, empirical and definite antibiotics use with duration of stay and outcome of patients. Among 40 cases of UTI; male to female ratio was 1:1 with mean age of 51.3± 16.32 years. Fever was present in almost all (97.5%) of the patients and three-fourth (75%) of them had dysuria. Type-2 Diabetes Mellitus was most common (55%) underlying condition and mean HbA1c was 9.37±2.27 followed by obstructive uropathy (17.50%). Most of cases (82.5%) were of complicated UTI; where Pyelonephritis was 42%, Emphysematous Pyelonephritis 12.5% and Renal Abscess 7.5%. Most common (37.5%) organism isolated from urine/ pus culture was Escherichia coli. More than half of the patients (55%) were given empirical antibiotics injection piperacillin tazobactam and carbapenems was used in more than one third (35%) of patients. The mean duration of antibiotics use was 14.55±4.94 days. Two (5.0%) patients expired out during the study period. Uncontrolled Diabetes Mellitus remains the major underlying condition in cases of complicated UTI. E coli is the most common organism isolated from urine/ pus culture. Most of the patients had favourable outcome with guided antibiotics and interventions. Bangladesh Med J. 2023 May; 52(2): 15-19
- 31 July 2024
- Published by Bangladesh Academy of Sciences in Bangladesh Medical Journal
- Vol. 52 (2) , 15-19
Open AccessClinical, Microbiological Profile and Antibiotics Use in Admitted Patients of Urinary Tract Infection
Urinary tract infections (UTI) can vary from simple cystitis to pyelonephritis with severe sepsis. The objective of this study is to provide information about the clinical and microbiological profile of admitted patients of urinary tract infection, patterns of organisms isolated, antibiotic sensitivity pattern and antibiotics use. It was a prospective observational study conducted on 40 patients age >14 years admitted with diagnosis of UTI based on clinical and microbiological criteria over 8 months at a tertiary care hospital in North India. Data was collected for the clinical, microbiological profile, empirical and definite antibiotics use with duration of stay and outcome of patients. Among 40 cases of UTI; male to female ratio was 1:1 with mean age of 51.3± 16.32 years. Fever was present in almost all (97.5%) of the patients and three-fourth (75%) of them had dysuria. Type-2 Diabetes Mellitus was most common (55%) underlying condition and mean HbA1c was 9.37±2.27 followed by obstructive uropathy (17.50%). Most of cases (82.5%) were of complicated UTI; where Pyelonephritis was 42%, Emphysematous Pyelonephritis 12.5% and Renal Abscess 7.5%. Most common (37.5%) organism isolated from urine/ pus culture was Escherichia coli. More than half of the patients (55%) were given empirical antibiotics injection piperacillin tazobactam and carbapenems was used in more than one third (35%) of patients. The mean duration of antibiotics use was 14.55±4.94 days. Two (5.0%) patients expired out during the study period. Uncontrolled Diabetes Mellitus remains the major underlying condition in cases of complicated UTI. E coli is the most common organism isolated from urine/ pus culture. Most of the patients had favourable outcome with guided antibiotics and interventions. Bangladesh Med J. 2023 May; 52(2): 15-19
- Open Access
- 1 January 2024
- Published by Georg Thieme Verlag KG in Journal of Gastrointestinal Infections
- Vol. 14 (01) , 001-002
Importance of Microbial Etiology and Antimicrobial Susceptibility Testing in Biliary Tract Infections
Biliary tract infections (BTIs) occur due to obstruction in the biliary tract either due to malignancy, choledocholithiasis, or cholelithiasis. BTIs cause bacteremia in approximately 20 to 80% of cholangitis cases leading to significantly high mortality in elderly and patients with comorbidities. Acute cholangitis can convert from a local infection to sepsis involving multiple organ failure. BTIs are not only the most common cause of community-acquired bacteremia but also hospital-acquired bacteremia. BTIs are associated with 9 to 12% mortality and this varies from 10 to 20% in cases of BTI-associated bacteremia.[1] In addition to clinical procedures, antibiotic treatment is needed to control infections. Most of the times, broad-spectrum antibiotics are empirically started as causative organism identification and antibiotic susceptibility testing takes some time. Mostly, antibiotic treatment in BTIs is directed toward suspected bacterial pathogens depending upon the epidemiological data of a particular region. Mortality rates of BTIs with bacteremia are high even with antibiotic treatment due to increase in the number of antibiotic-resistant pathogens. Multiple studies from different regions of the world have reported bacteria becoming increasingly multidrug resistant in the past few decades and it has been observed that the prominent pathogenic bacteria in BTIs have also become resistant to commonly prescribed antibiotics. During the last decade, extended-spectrum β-lactamase (ESBLs) producing Escherichia coli and Klebsiella pneumoniae have been reported to be increasingly associated with BTIs.[2] Drug resistance patterns have variations across different geographic regions because of varying economic conditions and also differences in antibiotic prescription practices. The study published in the previous issue of this journal by Gupta et al entitled as “Bacteriological and antimicrobial susceptibility profile in biliary tract infections: a retrospective study” described the Gram-negative bacteria as the predominant organisms in BTIs exhibiting high resistance to cephalosporins and carbapenems. The authors in this retrospective study conducted over a period of 1 year have brought attention to the burning issue of ever-increasing antimicrobial resistance (AMR) particularly against Gram-negative organisms. Authors have discussed the issue of BTIs with increased frequency of ESBLs and carbapenemase-producing Enterobacteriaceae family, making empiric antibiotic therapy ineffective. The study looked into the pathogen profile and antibiotic susceptibility patterns of isolates from patients suffering with BTIs in North Indian population as local data is scarce. The AMR is a global threat; however, the epidemiology of infections and current AMR profiles of different pathogens differ from one geographical region to other and even there is a great difference in antimicrobial profiles of isolated pathogens from developing and developed countries. Like other studies, in this study also Gram-negative bacilli (E. coli being the predominant) were more frequent than Gram-positive cocci (Enterococcus spp. being the most common) in bile cultures. Klebsiella spp. and Pseudomonas spp. reported high levels of resistance against cephalosporins and carbapenems. Moreover, approximately 70% of Gram-negative isolates exhibited multidrug resistance and ESBLs as well as carbapenemase producers were in majority.[3] This study highlighted that all the Gram-negative isolates exhibited high levels of resistance against β-lactam drugs including cephalosporins, penicillin, and β-lactamase inhibitor combinations, making the antibiotic treatment difficult for these organisms causing BTIs. Penicillin and cephalosporin should be used with utmost caution for treating patients infected with pathogenic ESBLs. This underscores the need to closely monitor the AMR profiles of BTI pathogens. As BTIs are associated with high morbidity and mortality particularly in population having underlying comorbidities, an urgent and efficacious treatment is need of the hour in such infections. Therefore, the knowledge about the predominant pathogens and their antimicrobial susceptibility profiles is essential to make right empirical choices. The only drawback of the study is that the details of antibiotics used empirically before receiving the bile cultures were missing. Antimicrobial therapy is must for patients with moderate to severe acute cholecystitis to control local inflammation as well as systemic septic response following cholecystectomy. Appropriate antibiotics should be administered within an hour for septic shock patients and within 6 hours of diagnosis for others. Therefore, initial therapy relies on the effective empiric antibiotics which are already reported and this varies across geographic regions.[1] BTI patients with choledocholithiasis need timely and relevant antibiotics (based on antimicrobial susceptibility considerations) together with adequate biliary drainage as this is the key effective treatment strategy. Therefore, antibiotics should be administered according to local pathogen spectrum and broad-spectrum antibiotics should be avoided or minimized. A recent study from China has demonstrated a significant change in the bacterial profile of bile from patients with choledocholithiasis and BTIs. Contrary to the above discussed study, the study from China showed that the Gram-positive cocci numbers increased annually, whereas Gram-negative bacilli and particularly E. coli incidences decreased in BTIs.[4] This study from North India is an important step toward understanding the characteristic profiles of pathogens causing biliary infections and underlying risk factors in these patients. This would further be useful in guiding clinical decisions to encourage rational use of antibiotics and in controlling multidrug-resistant bacterial infections. In conclusion, utmost care should be taken for...
- 1 January 2024
- Published by Georg Thieme Verlag KG in Journal of Gastrointestinal Infections
- Vol. 14 (01) , 001-002
Open AccessImportance of Microbial Etiology and Antimicrobial Susceptibility Testing in Biliary Tract Infections
Biliary tract infections (BTIs) occur due to obstruction in the biliary tract either due to malignancy, choledocholithiasis, or cholelithiasis. BTIs cause bacteremia in approximately 20 to 80% of cholangitis cases leading to significantly high mortality in elderly and patients with comorbidities. Acute cholangitis can convert from a local infection to sepsis involving multiple organ failure. BTIs are not only the most common cause of community-acquired bacteremia but also hospital-acquired bacteremia. BTIs are associated with 9 to 12% mortality and this varies from 10 to 20% in cases of BTI-associated bacteremia.[1] In addition to clinical procedures, antibiotic treatment is needed to control infections. Most of the times, broad-spectrum antibiotics are empirically started as causative organism identification and antibiotic susceptibility testing takes some time. Mostly, antibiotic treatment in BTIs is directed toward suspected bacterial pathogens depending upon the epidemiological data of a particular region. Mortality rates of BTIs with bacteremia are high even with antibiotic treatment due to increase in the number of antibiotic-resistant pathogens. Multiple studies from different regions of the world have reported bacteria becoming increasingly multidrug resistant in the past few decades and it has been observed that the prominent pathogenic bacteria in BTIs have also become resistant to commonly prescribed antibiotics. During the last decade, extended-spectrum β-lactamase (ESBLs) producing Escherichia coli and Klebsiella pneumoniae have been reported to be increasingly associated with BTIs.[2] Drug resistance patterns have variations across different geographic regions because of varying economic conditions and also differences in antibiotic prescription practices. The study published in the previous issue of this journal by Gupta et al entitled as “Bacteriological and antimicrobial susceptibility profile in biliary tract infections: a retrospective study” described the Gram-negative bacteria as the predominant organisms in BTIs exhibiting high resistance to cephalosporins and carbapenems. The authors in this retrospective study conducted over a period of 1 year have brought attention to the burning issue of ever-increasing antimicrobial resistance (AMR) particularly against Gram-negative organisms. Authors have discussed the issue of BTIs with increased frequency of ESBLs and carbapenemase-producing Enterobacteriaceae family, making empiric antibiotic therapy ineffective. The study looked into the pathogen profile and antibiotic susceptibility patterns of isolates from patients suffering with BTIs in North Indian population as local data is scarce. The AMR is a global threat; however, the epidemiology of infections and current AMR profiles of different pathogens differ from one geographical region to other and even there is a great difference in antimicrobial profiles of isolated pathogens from developing and developed countries. Like other studies, in this study also Gram-negative bacilli (E. coli being the predominant) were more frequent than Gram-positive cocci (Enterococcus spp. being the most common) in bile cultures. Klebsiella spp. and Pseudomonas spp. reported high levels of resistance against cephalosporins and carbapenems. Moreover, approximately 70% of Gram-negative isolates exhibited multidrug resistance and ESBLs as well as carbapenemase producers were in majority.[3] This study highlighted that all the Gram-negative isolates exhibited high levels of resistance against β-lactam drugs including cephalosporins, penicillin, and β-lactamase inhibitor combinations, making the antibiotic treatment difficult for these organisms causing BTIs. Penicillin and cephalosporin should be used with utmost caution for treating patients infected with pathogenic ESBLs. This underscores the need to closely monitor the AMR profiles of BTI pathogens. As BTIs are associated with high morbidity and mortality particularly in population having underlying comorbidities, an urgent and efficacious treatment is need of the hour in such infections. Therefore, the knowledge about the predominant pathogens and their antimicrobial susceptibility profiles is essential to make right empirical choices. The only drawback of the study is that the details of antibiotics used empirically before receiving the bile cultures were missing. Antimicrobial therapy is must for patients with moderate to severe acute cholecystitis to control local inflammation as well as systemic septic response following cholecystectomy. Appropriate antibiotics should be administered within an hour for septic shock patients and within 6 hours of diagnosis for others. Therefore, initial therapy relies on the effective empiric antibiotics which are already reported and this varies across geographic regions.[1] BTI patients with choledocholithiasis need timely and relevant antibiotics (based on antimicrobial susceptibility considerations) together with adequate biliary drainage as this is the key effective treatment strategy. Therefore, antibiotics should be administered according to local pathogen spectrum and broad-spectrum antibiotics should be avoided or minimized. A recent study from China has demonstrated a significant change in the bacterial profile of bile from patients with choledocholithiasis and BTIs. Contrary to the above discussed study, the study from China showed that the Gram-positive cocci numbers increased annually, whereas Gram-negative bacilli and particularly E. coli incidences decreased in BTIs.[4] This study from North India is an important step toward understanding the characteristic profiles of pathogens causing biliary infections and underlying risk factors in these patients. This would further be useful in guiding clinical decisions to encourage rational use of antibiotics and in controlling multidrug-resistant bacterial infections. In conclusion, utmost care should be taken for...
- 1 December 2023
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 47, 100514
Neisseria mucosa: A not so Benign Culprit of urinary tract infection: A case report
- 1 December 2023
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 47, 100514
Neisseria mucosa: A not so Benign Culprit of urinary tract infection: A case report
- 11 October 2023
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 17 (10) , 102877
Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials
- 11 October 2023
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 17 (10) , 102877
Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials
- Open Access
- 1 July 2023
- Published by Georg Thieme Verlag KG in Journal of Gastrointestinal Infections
- Vol. 13 (02) , 092-094
Journal Summary: Syndromic Molecular Point-of-Care Testing for Gastrointestinal Pathogens versus Routine Microbiological Testing for Gastroenteritis
Brendish et al conducted a first of its kind large-scale randomized controlled trial to evaluate the clinical impact of syndromic molecular point-of-care testing (mPCOT) for gastrointestinal pathogens in adults hospitalized with suspected gastroenteritis.[1] An increasing number of pathogens have been identified to be the causative agents of diarrhea. Most of the times, diarrhea is self-limiting and manageable with fluid therapy, whereas the severe episodes can be life threatening and require optimal antimicrobial therapy that varies with the specific causative pathogen. The diagnosis of diarrheal pathogens has always been cumbersome and problematic by conventional approaches. Patients with diarrhea are typically placed in isolation in single occupancy rooms to prevent transmission of infectious pathogens to other patients as well healthcare staff. The National Health Services in United Kingdom has approximately 40,000 of these single occupancy rooms out of a total of 111,000 acute hospital beds, with only around 1,700 designated for isolation.[2] [3] Above-mentioned study was conducted during the coronavirus disease 2019 pandemic, causing further diagnostic delays and strained healthcare resources for patients with diarrhea seeking hospital admission and care. Authors studied 278 adult patients of diarrhea over a period of 3 years who were randomly assigned to either mPCOT (n = 137) group or routine clinical care group (n = 140). Patients admitted to the hospital with suspected gastroenteritis were recruited to study the clinical implications on various outcomes including utilization of a single occupancy room turn-around time of tests, time to de-isolation, antibiotic administration, and safety outcomes. Acute diarrheal illness was defined as three or more stools for at least 1 day. Inclusion criteria included patients who had acute diarrhea or vomiting for up to 14 days, were at least 18 years old, and could provide written consent. Recruitment occurred within 48 hours of first triage in an emergency or 48 hours of community admission to the acute medicine and surgical unit or inpatient ward. Patients allocated to the intervention group had a stool sample or rectal swab obtained and analyzed immediately by Film-Array Gastrointestinal Panel (BioFire Diagnostics, bioMérieux, Salt Lake City, Utah, United States). Patients who were randomly assigned to receive routine clinical care (i.e., control group) had stool testing done by standard laboratory testing at the discretion of the clinical team. In the mPCOT group, patients spent 1.8 days (95% confidence interval: 1.5–2.2) in a single occupancy room compared with 2.6 days (2.2–3.0) in the control group, signifying a 30% reduction (p = 0.0017). This reduction remained significant when considering multiple factors. Patients without detected pathogens in the mPCOT group had a shorter stay (1.3 days 1.0–1.6), while no difference was noted in hospital stay duration between groups for patients with detected pathogens (2.8 days in mPCOT vs. 2.9 days in control, p = 0.76). Time-to-event analysis revealed quicker deisolation after mPCOT, driven by patients in the mPCOT group with no detected pathogen. The median time for clinicians to access results was 1.7 hours in the mPCOT group versus 44.7 hours in the control group (p = 0.0001). More patients in the mPCOT group moved from single occupancy to shared bay areas during hospitalization. More pathogens were detected in the mPCOT group (45 vs. 26%, p = 0.0007), with Campylobacter species being the most common. Patients in the mPCOT received more antibiotics (65 vs. 47%, p = 0.0028), particularly with a final diagnosis of gastroenteritis. Although inappropriate antibiotic use was similar, the mPCOT group received shorter durations of such antibiotics nearly by 4 days. This demonstrated that the clinicians who acted upon mPCOT results either shifted to appropriate antibiotics based on the detected pathogen or discontinued antibiotics. It highlights the potency of mPCOT as an antibiotic stewardship intervention. Implementing this strategy may further enhance clinical benefits and enable more targeted therapy. Concordance between rectal swabs and stool samples for pathogen detection was high with a negative predictive value of 91%. There was a notable use of higher antibiotics in mPCOT group as compared with the control group that raises concerns about the potential overtreatment of colonizing organisms like Clostridioides difficile. However, the study reveals that the use was primarily driven by a larger proportion of patients with gastroenteritis receiving antibiotics, particularly for those with Campylobacter and enteropathogenic Escherichia coli, not Clostridioides difficile. A prior small-scale study in the emergency department showed improved pathogen-directed antibiotic use with mPCOT but did not assess its impact on infection control measures.[4] In contrast, a randomized controlled trial with laboratory-based molecular testing in hospitalized adults, which enrolled approximately half the number of patients as this study, found no difference in isolation facility utilization or other clinical outcomes.[5] Another trial done in Botswana involving children using a test-and-treat strategy with rapid molecular testing did not yield improved outcomes, although the study was significantly underpowered.[6] In this study, the absence of differences in hospital stays length and other clinical measures between groups that factors such as age and comorbidities may be more influential determinants. Roughly a quarter of participants had inflammatory bowel disease (IBD), prompting further research into mPCOT use in IBD rapid access clinics, including outcomes related to admission avoidance, antibiotic use, and steroid treatment. Pathogen detection using rectal swabs and stool samples on the Film-Array platform showed high concordance supporting the use of routine rectal swabs to...
- 1 July 2023
- Published by Georg Thieme Verlag KG in Journal of Gastrointestinal Infections
- Vol. 13 (02) , 092-094
Open AccessJournal Summary: Syndromic Molecular Point-of-Care Testing for Gastrointestinal Pathogens versus Routine Microbiological Testing for Gastroenteritis
Brendish et al conducted a first of its kind large-scale randomized controlled trial to evaluate the clinical impact of syndromic molecular point-of-care testing (mPCOT) for gastrointestinal pathogens in adults hospitalized with suspected gastroenteritis.[1] An increasing number of pathogens have been identified to be the causative agents of diarrhea. Most of the times, diarrhea is self-limiting and manageable with fluid therapy, whereas the severe episodes can be life threatening and require optimal antimicrobial therapy that varies with the specific causative pathogen. The diagnosis of diarrheal pathogens has always been cumbersome and problematic by conventional approaches. Patients with diarrhea are typically placed in isolation in single occupancy rooms to prevent transmission of infectious pathogens to other patients as well healthcare staff. The National Health Services in United Kingdom has approximately 40,000 of these single occupancy rooms out of a total of 111,000 acute hospital beds, with only around 1,700 designated for isolation.[2] [3] Above-mentioned study was conducted during the coronavirus disease 2019 pandemic, causing further diagnostic delays and strained healthcare resources for patients with diarrhea seeking hospital admission and care. Authors studied 278 adult patients of diarrhea over a period of 3 years who were randomly assigned to either mPCOT (n = 137) group or routine clinical care group (n = 140). Patients admitted to the hospital with suspected gastroenteritis were recruited to study the clinical implications on various outcomes including utilization of a single occupancy room turn-around time of tests, time to de-isolation, antibiotic administration, and safety outcomes. Acute diarrheal illness was defined as three or more stools for at least 1 day. Inclusion criteria included patients who had acute diarrhea or vomiting for up to 14 days, were at least 18 years old, and could provide written consent. Recruitment occurred within 48 hours of first triage in an emergency or 48 hours of community admission to the acute medicine and surgical unit or inpatient ward. Patients allocated to the intervention group had a stool sample or rectal swab obtained and analyzed immediately by Film-Array Gastrointestinal Panel (BioFire Diagnostics, bioMérieux, Salt Lake City, Utah, United States). Patients who were randomly assigned to receive routine clinical care (i.e., control group) had stool testing done by standard laboratory testing at the discretion of the clinical team. In the mPCOT group, patients spent 1.8 days (95% confidence interval: 1.5–2.2) in a single occupancy room compared with 2.6 days (2.2–3.0) in the control group, signifying a 30% reduction (p = 0.0017). This reduction remained significant when considering multiple factors. Patients without detected pathogens in the mPCOT group had a shorter stay (1.3 days 1.0–1.6), while no difference was noted in hospital stay duration between groups for patients with detected pathogens (2.8 days in mPCOT vs. 2.9 days in control, p = 0.76). Time-to-event analysis revealed quicker deisolation after mPCOT, driven by patients in the mPCOT group with no detected pathogen. The median time for clinicians to access results was 1.7 hours in the mPCOT group versus 44.7 hours in the control group (p = 0.0001). More patients in the mPCOT group moved from single occupancy to shared bay areas during hospitalization. More pathogens were detected in the mPCOT group (45 vs. 26%, p = 0.0007), with Campylobacter species being the most common. Patients in the mPCOT received more antibiotics (65 vs. 47%, p = 0.0028), particularly with a final diagnosis of gastroenteritis. Although inappropriate antibiotic use was similar, the mPCOT group received shorter durations of such antibiotics nearly by 4 days. This demonstrated that the clinicians who acted upon mPCOT results either shifted to appropriate antibiotics based on the detected pathogen or discontinued antibiotics. It highlights the potency of mPCOT as an antibiotic stewardship intervention. Implementing this strategy may further enhance clinical benefits and enable more targeted therapy. Concordance between rectal swabs and stool samples for pathogen detection was high with a negative predictive value of 91%. There was a notable use of higher antibiotics in mPCOT group as compared with the control group that raises concerns about the potential overtreatment of colonizing organisms like Clostridioides difficile. However, the study reveals that the use was primarily driven by a larger proportion of patients with gastroenteritis receiving antibiotics, particularly for those with Campylobacter and enteropathogenic Escherichia coli, not Clostridioides difficile. A prior small-scale study in the emergency department showed improved pathogen-directed antibiotic use with mPCOT but did not assess its impact on infection control measures.[4] In contrast, a randomized controlled trial with laboratory-based molecular testing in hospitalized adults, which enrolled approximately half the number of patients as this study, found no difference in isolation facility utilization or other clinical outcomes.[5] Another trial done in Botswana involving children using a test-and-treat strategy with rapid molecular testing did not yield improved outcomes, although the study was significantly underpowered.[6] In this study, the absence of differences in hospital stays length and other clinical measures between groups that factors such as age and comorbidities may be more influential determinants. Roughly a quarter of participants had inflammatory bowel disease (IBD), prompting further research into mPCOT use in IBD rapid access clinics, including outcomes related to admission avoidance, antibiotic use, and steroid treatment. Pathogen detection using rectal swabs and stool samples on the Film-Array platform showed high concordance supporting the use of routine rectal swabs to...
- Open Access
- 23 February 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-14
Frequency, outcomes, and need for intervention in stricturing gastrointestinal tuberculosis: a systematic review and meta-analysis
Background: Gastrointestinal strictures impact clinical presentation in abdominal tuberculosis and are associated with significant morbidity.Aim: To conduct a systematic review of the prevalence of stricturing disease in abdominal and gastrointestinal tuberculosis and response to antitubercular therapy (ATT).Methods: We searched Pubmed and Embase on 13th January 2022, for papers reporting on the frequency and outcomes of stricturing gastrointestinal tuberculosis. The data were extracted, and pooled prevalence of stricturing disease was estimated in abdominal tuberculosis and gastrointestinal (intestinal) tuberculosis. The pooled clinical response and stricture resolution (endoscopic or radiologic) rates were also estimated. Publication bias was assessed using the Funnel plot and Egger test. The risk of bias assessment was done using a modified Newcastle Ottawa Scale.Results: Thirty-three studies reporting about 1969 patients were included. The pooled prevalence of intestinal strictures in abdominal tuberculosis and gastrointestinal TB was 0.12 (95%CI 0.07–0.20, I2 = 89%) and 0.27 (95% CI 0.21–0.33, I2 = 85%), respectively. The pooled clinical response of stricturing gastrointestinal tuberculosis to antitubercular therapy was 0.77 (95%CI 0.65–0.86, I2 = 74%). The pooled stricture response rate (endoscopic or radiological) was 0.66 (95%CI 0.40–0.85, I2 = 91%). The pooled rate of need for surgical intervention was 0.21 (95%CI 0.13–0.32, I2 = 70%), while endoscopic dilatation was 0.14 (95%CI 0.09–0.21, I2 = 0%).Conclusion: Stricturing gastrointestinal tuberculosis occurs in around a quarter of patients with gastrointestinal tuberculosis, and around two-thirds of patients have a clinical response with antitubercular therapy. A subset of patients may need endoscopic or surgical intervention. The estimates for the pooled prevalence of stricturing disease and response to ATT had significant heterogeneity.
- 23 February 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-14
Open AccessFrequency, outcomes, and need for intervention in stricturing gastrointestinal tuberculosis: a systematic review and meta-analysis
Background: Gastrointestinal strictures impact clinical presentation in abdominal tuberculosis and are associated with significant morbidity.Aim: To conduct a systematic review of the prevalence of stricturing disease in abdominal and gastrointestinal tuberculosis and response to antitubercular therapy (ATT).Methods: We searched Pubmed and Embase on 13th January 2022, for papers reporting on the frequency and outcomes of stricturing gastrointestinal tuberculosis. The data were extracted, and pooled prevalence of stricturing disease was estimated in abdominal tuberculosis and gastrointestinal (intestinal) tuberculosis. The pooled clinical response and stricture resolution (endoscopic or radiologic) rates were also estimated. Publication bias was assessed using the Funnel plot and Egger test. The risk of bias assessment was done using a modified Newcastle Ottawa Scale.Results: Thirty-three studies reporting about 1969 patients were included. The pooled prevalence of intestinal strictures in abdominal tuberculosis and gastrointestinal TB was 0.12 (95%CI 0.07–0.20, I2 = 89%) and 0.27 (95% CI 0.21–0.33, I2 = 85%), respectively. The pooled clinical response of stricturing gastrointestinal tuberculosis to antitubercular therapy was 0.77 (95%CI 0.65–0.86, I2 = 74%). The pooled stricture response rate (endoscopic or radiological) was 0.66 (95%CI 0.40–0.85, I2 = 91%). The pooled rate of need for surgical intervention was 0.21 (95%CI 0.13–0.32, I2 = 70%), while endoscopic dilatation was 0.14 (95%CI 0.09–0.21, I2 = 0%).Conclusion: Stricturing gastrointestinal tuberculosis occurs in around a quarter of patients with gastrointestinal tuberculosis, and around two-thirds of patients have a clinical response with antitubercular therapy. A subset of patients may need endoscopic or surgical intervention. The estimates for the pooled prevalence of stricturing disease and response to ATT had significant heterogeneity.
- 13 January 2023
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (2) , 147-148
Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”
- 13 January 2023
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (2) , 147-148
Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”